docetaxel anhydrous

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

USFDA’s list of drugs that need generic alternatives

In its continuous endeavor to bolster the competitiveness of the generics market, the US Food

Top drugs and pharmaceutical companies of 2019 by revenues

Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-

Emcure’s Import Alert: Is there a way of knowing who will be next?

The U.S. FDA banned drug imports from the finished dosage form operations of Emcure Pharmaceutic

Marijuana Based Medicines – highway to pots of gold

Legally cultivated cannabis, in some parts of the United States, resulted in a boom, which could ne

Dr. Reddy’s expansion plans for API production

Unrelated to the inspection of the USFDA at the Dr. Reddys Srikakulam facility, Dr. Reddys sought pe

Cabazitaxel –The Market Overcrowding Begins

Many companies have been actively developing Cabazitaxel (Jevtana Kit®), a prostate cancer drug